Acro Biomedical Co., Ltd. (ACBM)

Acro Biomedical Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	-	-	0.66	1.2
Revenue Growth (YoY)	-	-	-	-	-45.01%	74.06%
Cost of Revenue	-	-	-	-	0.52	0.94
Gross Profit	-	-	-	-	0.14	0.26
Selling, General & Admin	0.21	0.15	0.04	3.52	5.93	2.67
Research & Development	-	-	-	4.79	10.08	5.29
Operating Expenses	0.21	0.15	0.04	8.79	16.01	7.95
Operating Income	-0.21	-0.15	-0.04	-8.79	-15.87	-7.69
Interest Expense	-0.01	-0.01	-0	-0	-0	-0
EBT Excluding Unusual Items	-0.22	-0.16	-0.04	-8.8	-15.87	-7.7
Asset Writedown	-	-	-	-0.01	-	-
Other Unusual Items	0.08	0.06	-	-	-	-
Pretax Income	-0.13	-0.1	-0.04	-8.81	-15.87	-7.7
Net Income	-0.13	-0.1	-0.04	-8.81	-15.87	-7.7
Net Income to Common	-0.13	-0.1	-0.04	-8.81	-15.87	-7.7
Shares Outstanding (Basic)	60	60	60	60	60	54
Shares Outstanding (Diluted)	60	60	60	60	60	54
Shares Change (YoY)	-	-	-	-	11.52%	12.73%
EPS (Basic)	-0.00	-0.00	-0.00	-0.15	-0.26	-0.14
EPS (Diluted)	-0.00	-0.00	-0.00	-0.15	-0.26	-0.14
Gross Margin	-	-	-	-	21.34%	21.67%
Operating Margin	-	-	-	-	-2409.98%	-642.47%
Profit Margin	-	-	-	-	-2410.24%	-642.83%
EBIT	-0.21	-0.15	-0.04	-8.79	-15.87	-7.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.